基本信息
浏览量:5
职业迁徙
个人简介
Dr. Gabrilove is the recipient of a patent for the discovery of human granulocyte colony stimulating factor (G-CSF), and was the first to demonstrate that it could alleviate certain harmful effects of chemotherapy on blood-cell production. G-CSF, now produced commercially by Amgen, Inc. under the trade-name Neupogen & Neulasta, is used worldwide as a supplement to chemotherapy. Dr. Gabrilove was the first to report on the ability of G-CSF to mobilize progenitors into the peripheral blood, an observation which has revolutionized the way in which bone-marrow transplantation is performed with the development of peripheral blood stem-cell transplants. Dr. Gabrilove has been intimately in the development of novel therapeutics for fostering leukemic cell maturation, and has been awarded patents for two additional drugs, approved by the FDA, for the treatment of myeloid leukemia
研究兴趣
论文共 28 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn